Anzeige
Mehr »
Lynx Broker
Login
Dienstag, 12.11.2019 Börsentäglich über 12.000 News von 617 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
29.06.2010 | 08:02
(47 Leser)
(0 Bewertungen)
29 June 2010

                             Scancell Holdings Plc                             

                         ('Scancell' or the 'Company')                         

                    Research collaboration with immatics to                    

           develop novel ImmunoBody® vaccines for colorectal cancer            

Scancell Holdings Plc, (PLUS:SCLP), the developer of therapeutic cancer
vaccines, today announces a research collaboration with immatics
biotechnologies GmbH ("immatics") to explore the development of novel
ImmunoBody® vaccines for colorectal cancer.

immatics discovers and develops tumor-associated peptides (TUMAPs) for the
immunotherapy of cancer. TUMAPs with the highest specificity for particular
cancers are identified directly from primary human tumour tissue samples. From
thousands of identified TUMAPs the most suitable ones are selected and combined
to a single multi-peptide product to form a therapeutic cancer vaccine. The
goal is to provoke a number of specific T-cell responses which finally result
in the destruction of tumour cells presenting the TUMAPs.

immatics' most advanced product, IMA901, has been evaluated in a Europe-wide
multi-centre Phase II clinical trial in renal cancer. Positive data of this
Phase II study have recently been published at the ASCO 2010 meeting. immatics'
pipeline also includes IMA910 for the treatment of colorectal carcinoma
which has recently entered a large Phase I/II clinical trial.

Scancell's first vaccine using its patented ImmunoBody® technology is SCIB1, a
novel DNA vaccine being developed for the treatment of melanoma, which is
currently in Phase 1 clinical trials. An advantage of Scancell's Immunobody®
platform is that it specifically targets dendritic* cells, leading to a
significant enhancement of the immune response. This enhanced immune response
against TRP-2 (a melanoma protein called Tyrosinase-Related Protein 2) is
anticipated to lead to the inhibition and regression of both primary and
metastatic melanoma tumour growth.

In the research collaboration with immatics, colorectal cancer-specific TUMAPs
will be incorporated into ImmunoBody® constructs to create ImmunoBody® vaccines
targeted towards colorectal cancer. If the research project is successful,
immatics and Scancell will explore the further development of any product
candidates.

Paul Higham, CEO of Immatics said: "'We are very pleased to enter this research
collaboration with Scancell as the colorectal TUMAPs identified by immatics
have the potential to complement and enhance Scancell's ImmunoBody technology.
We eagerly await the results."

Professor Lindy Durrant, Chief Executive Officer of Scancell, commented: "Our
research collaboration with immatics will create the opportunity to bring
together two world class technologies. We will be working together with
immatics to evaluate the combination of the immatics' TUMAP technology with
Scancell's ImmunoBody® technology for the development of novel vaccines for the
treatment of colorectal cancer."

* A type of white blood cell that initiates an immune response

A copy of this announcement is available for download on the Company's website
at http://www.scancell.co.uk/

The Directors of the issuer accept responsibility for this announcement.

-ENDS-

For further information contact:

Professor Lindy Durrant  Scancell Holdings Plc       tel: + 44 (0)207 245 1100 
                                                                               
Katrin Eckert, Assistant immatics biotechnologies    tel: +49 (0)7071 5397 110 
to the Management        GmbH                                                  
                                                     email: media@immatics.com 
                                                                               
John Bick/Kirsty         Hansard Communications      tel: + 44 (0)207 245 1100 
Corcoran                                                                       
                                                     tel: + 44 (0)7872 061 007 
                                                                               
Ross Andrews/Tom Rowley  Zeus Capital                tel: + 44 (0)161 831 1512 

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer
and infectious diseases based on its groundbreaking ImmunoBody® technology
platform. Scancell's first cancer vaccine SCIB1 is being developed for the
treatment of melanoma and is currently in Phase 1 clinical trials.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a patient, stimulating an immune response. Effective cancer
vaccines need to target dendritic cells to stimulate both parts of the cellular
immune system; the helper cell system where inflammation is stimulated at the
tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system
cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they
cannot specifically target dendritic cells in vivo. Several groups have
demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing
them with tumour antigens and re-infusing them. However, this procedure is
patient specific, time consuming and expensive. Scancell has developed its
breakthrough patent protected ImmunoBody® technology to overcome these
limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express
helper cell and CTL epitopes from tumour antigens over-expressed by cancer
cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour
antigens as they have long half-lives and can effectively target dendritic
cells via their Fc receptors, allowing efficient stimulation of both helper and
CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any
tumour type and may also be of potential utility in the development of vaccines
against hepatitis, HIV and other chronic infectious diseases.

About Immatics

immatics biotechnologies is a clinical-stage biopharmaceutical company
developing advanced therapeutic vaccines that are active against cancer.
immatics' lead product, IMA901 has completed a successful Phase II trial in
renal cell carcinoma. immatics' pipeline also includes IMA910, in Phase II for
colorectal cancer, and IMA950 which is being developed for glioma.

immatics' technology platform rapidly generates defined therapeutic cancer
vaccines which are based on multiple tumor-associated peptides (TUMAPs) with
the ability to specifically stimulate the immune system against cancer cells.
These vaccines - comprising multiple peptides confirmed to be naturally
presented by real tumor tissue - offer the prospect of greater effectiveness
than existing cancer vaccine approaches combined with fewer side effects.
immatics' products are 'drug like' with stable, off -the- shelf formulations
and robust easily scalable manufacturing. www.immatics.com



END

SCANCELL HOLDINGS PLC


© 2010 PR Newswire